These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10051059)

  • 21. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants.
    Gardiner SJ; Kristensen JH; Begg EJ; Hackett LP; Wilson DA; Ilett KF; Kohan R; Rampono J
    Am J Psychiatry; 2003 Aug; 160(8):1428-31. PubMed ID: 12900304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.
    Olesen OV; Poulsen B; Linnet K
    Ther Drug Monit; 2001 Feb; 23(1):51-5. PubMed ID: 11206044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
    Bergemann N; Frick A; Parzer P; Kopitz J
    Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic?
    Robertson MD; McMullin MM
    J Forensic Sci; 2000 Mar; 45(2):418-21. PubMed ID: 10782964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
    Melkersson KI; Hulting AL; Brismar KE
    J Clin Psychiatry; 2000 Oct; 61(10):742-9. PubMed ID: 11078035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring.
    Llorca PM; Coudore F; Corpelet C; Buyens A; Hoareau M; Eschalier A
    Clin Chem; 2001 Sep; 47(9):1719-21. PubMed ID: 11514415
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose olanzapine and prolactin levels.
    Karagianis JL; Baksh A
    J Clin Psychiatry; 2003 Oct; 64(10):1192-4. PubMed ID: 14658967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine overdose with serum concentrations.
    Cohen LG; Fatalo A; Thompson BT; Di Centes Bergeron G; Flood JG; Poupolo PR
    Ann Emerg Med; 1999 Aug; 34(2):275-8. PubMed ID: 10424935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
    Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
    Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.
    Fekete S; Wewetzer C; Mehler-Wex C; Holtkamp K; Burger R; Reichert S; Taurines R; Romanos M; Gerlach M; Egberts K
    Ther Drug Monit; 2017 Jun; 39(3):273-281. PubMed ID: 28383317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
    Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL
    J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection.
    Gervasini G; Vizcaíno S; Herráiz AG; Benítez J; Carrillo JA
    Clin Chem; 2003 Dec; 49(12):2088-91. PubMed ID: 14633885
    [No Abstract]   [Full Text] [Related]  

  • 33. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
    Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
    Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
    Kelly DL; Conley RR; Tamminga CA
    Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol.
    Linnet K; Wiborg O
    Ther Drug Monit; 1996 Dec; 18(6):629-34. PubMed ID: 8946657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine: interaction study with imipramine.
    Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV
    J Clin Pharmacol; 1997 Oct; 37(10):971-8. PubMed ID: 9505989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
    Spina E; D'Arrigo C; Santoro V; Muscatello MR; Pandolfo G; Zoccali R; Diaz FJ; de Leon J
    Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
    Tveito M; Smith RL; Høiseth G; Molden E
    J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.